The MIF -173G/C gene polymorphism increase gastrointestinal cancer and hematological malignancy risk: evidence from a meta-analysis and FPRP test

• Published in: International journal of clinical and experimental medicine 2015-01, Vol.8 (9), p.15949-15957
• Main Authors: Tong, Xiang, Zheng, Bing, Tong, Qiaoyi, Liu, Sitong, Peng, Sifeng, Yang, Xin, Fan, Hong
• Format: Article
• Language: English
• Subjects: Original
• ISSN: 1940-5901; 1940-5901

The macrophage migration inhibitory factor (MIF) -173G/C gene polymorphism has been implicated in the susceptibility to cancer, but the results are not conclusive. So the aim of study to investigate the association between MIF -173G/C gene polymorphism and cancer risk by a comprehensive meta-analysis. We searched the PubMed, Embase, Wanfang and China National Knowledge Internet (CNKI) databases, with the last updated search being performed on May 24, 2015. The odds ratio (OR) and 95% confidence interval (95% CI) were used to assess the association. Statistical analysis was performed by STATA 11.0 software. Finally, 7,253 participants from 15 studies were included in the meta-analysis. The results of meta-analysis indicated the significant association between MIF -173G/C gene polymorphism and cancer susceptibility, especially in Asians (C vs. 1.22, 95% CI=1.00-1.50). In addition, the significant relationship between MIF -173G/C gene polymorphism and gastrointestinal tumors (CC+CG vs. 1.25, 95% CI=1.05-1.50), hematological malignancy (CC+CG vs. 1.27, 95% CI=1.03-1.56), gynecolgical tumors (CC vs. CG+ 1.51, 95% CI=1.04-2.19) risk was found. However, to avoid the "false positive report", we investigated the significant associations observed in the present meta-analysis by the false positive report probabilities (FPRPs) test. Interestingly, the results of FPRP test indicated the MIF -173G/C gene polymorphism only associated with gastrointestinal cancer and hematological malignancy risk (FPRP=0.132, 0.067 respectively) at the level of a prior probability is 0.1. Therefore, the meta-analysis suggested MIF -173G/C gene polymorphism would be a risk factor for the gastrointestinal cancer and hematological malignancy.